With extensive experience in the industry, a new director has been appointed to position the company for growth. This individual brings an impressive knowledge base and the ambition to take the company to the next level of success. With their leadership, the company is well-poised to reach its goals and thrive.
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a mission to improve the lives of patients through the use of neurohealth therapies, is proud to announce the appointment of Joseph H. Capper to its Board of Directors and Audit Committee effective January 1, 2023. With his strategic vision and experience, Capper is set to play a key role in helping Neuronetics realize its vision of providing the best neurohealth therapies in the world to patients in need.
Joe is an esteemed figure in the medical technology space, renowned for his skill in helping companies reach their ambitions. His extensive knowledge of public companies and enthusiasm for pioneering medical technologies make him an invaluable addition to Neuronetics’ Board of Directors, a plus for the organization and a boon to the patients that depend on its mental health services. Rob Cascella, Chairman of the Board of Neuronetics, praised Joe’s appointment, saying, “Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals.”
Joe Capper brings a wealth of experience in the medical technology and life sciences industries to the Company. Most recently, he served as President and Chief Executive Officer of BioTelemetry, Inc (formerly Nasdaq: BEAT). Prior to that, Joe spent nine years with Bayer Corporation where he eventually became the National Sales Director of the Diabetic Products Division. Joe has also served honorably in the U.S. Navy as a combat aviator and later as a congressional liaison. He holds an undergraduate degree in accounting from West Chester University and an MBA in International Finance from George Washington University. With over 30 years of experience in the med-tech and life sciences market, Joe is an invaluable asset to the Company.
The mental health crisis that has been exacerbated by the pandemic has made Neuronetics’ technology more important than ever. I am inspired by the company’s mission to revolutionize neurohealth, and I am excited to be part of their journey to success.
At Neuronetics, we understand the importance of mental health and its impact on overall wellbeing. That’s why we’ve developed NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for a range of neurohealth conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression. NeuroStar is the leading transcranial magnetic stimulation (TMS) treatment for MDD, with over 5 million treatments delivered and the world’s largest depression Outcomes Registry. Our goal is to help people suffering from these conditions rediscover their quality of life and experience extraordinary results.
“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:
Neuronetics, Inc. (the “Company”) has issued a press release containing forward-looking statements that are subject to a number of risks and uncertainties. These statements may include terms such as “outlook,” “potential,” “believe,” “expect,” “plan,” “anticipate,” “predict,” “may,” “will,” “could,” “would” and “should.” Factors that could lead to actual results differing from those projected include the Company’s ability to achieve or sustain profitable operations, reliance on the sale and usage of its NeuroStar Advanced Therapy System to generate revenues, availability of coverage and reimbursement from third-party payors, physician and patient demand for treatments, developments in respect of competing technologies, product defects, and the Company’s ability to obtain and maintain intellectual property protection. For a full discussion of the risks and uncertainties related to the Company’s forward-looking statements, please refer to the Company’s recent SEC filings.